AstraZeneca stock after-hours at EUR 145.23: minus 0.63 percent versus prior close
Published on 09/29/2026 at 19:50 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
AstraZeneca stock was at EUR 145.23 in after-hours trading at 7:45 p.m. CEST on September 29, 2026, down EUR 0.92, or minus 0.63 percent, versus the EUR 146.15 prior close at Lang & Schwarz.
Trading day
The Lang & Schwarz quote was recorded on September 29, 2026. The bid was EUR 144.95 and the ask was EUR 145.50.
Summit investment and cancer collaboration
On September 28, 2026, AstraZeneca announced an agreement to invest $2 billion in newly issued equity of Summit Therapeutics to support development of ivonescimab in combination with antibody-drug conjugates. AstraZeneca said the companies also agreed to evaluate sonesitatug vedotin with ivonescimab in gastrointestinal cancers.
Under the announced terms, AstraZeneca will purchase approximately 109,000 preferred shares convertible into Summit common stock at a 1:1,000 ratio. Following completion, AstraZeneca is expected to hold rights equivalent to approximately 12.0 percent of Summit’s outstanding common stock, or approximately 10.6 percent on a fully diluted basis. Closing was anticipated within one week, according to the company release.
Priority Review for bladder-cancer application
In a September 25, 2026 release, AstraZeneca said the US Food and Drug Administration accepted and granted Priority Review to its supplemental biologics license application for Imfinzi combined with enfortumab vedotin in certain patients with muscle-invasive bladder cancer. The FDA action date was anticipated in the fourth quarter of 2026, according to AstraZeneca.
